RxDoctor Payments Data

Zhengjin Cao, MD

Internal Medicine · Dubuque, IANPI 1861616039

Payments from drug & device makers

$1,502in general payments, 2019–2025

Across 71 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$564
  • Astellas Pharma US Inc$221
  • AbbVie$205
  • Johnson & Johnson$175
  • Pfizer$82
  • AstraZeneca$47
  • plus $207 from 10 others

What the payments were for

  • Travel & lodging$56438%
  • Food & beverage$74049%
  • Education$19813%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,502 in reported general payments places this provider in the 85th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$215,876
Medicare patients
391
Services billed
9,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide225$258,284
EliquisApixaban258$198,912
JardianceEmpagliflozin94$128,422
XareltoRivaroxaban124$116,778
FarxigaDapagliflozin Propanediol100$80,024
MounjaroTirzepatide52$58,621
Breo ElliptaFluticasone/Vilanterol84$40,946
JanuviaSitagliptin Phosphate47$40,870
XifaxanRifaximin12$38,531
MyrbetriqMirabegron77$38,196
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$30,518
Tresiba Flextouch U-100Insulin Degludec26$22,667
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$18,257
Bydureon BciseExenatide Microspheres20$16,769
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$16,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Levemir$18$278,174252 claims
PfizerEliquis$82$198,912258 claims
Johnson & JohnsonXarelto$175$116,778124 claims
AstraZenecaFarxiga, Brilinta$47$88,338117 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$34$83,830146 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$35$80,21782 claims
Astellas Pharma US IncMyrbetriq$221$38,19677 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Dubuque

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →